Celadon Pharmaceuticals PLC Results of Feasibility Study (2589L)
December 30 2022 - 1:00AM
UK Regulatory
TIDMCEL
RNS Number : 2589L
Celadon Pharmaceuticals PLC
30 December 2022
Celadon Pharmaceuticals Plc
("Celadon" or the "Group")
Results of Feasibility Study Submitted to Research Ethics
Committee for Approval
London, 30 December 2022 - Celadon Pharmaceuticals Plc (AIM:
CEL) , a UK-based pharmaceutical company focused on the research,
cultivation, manufacturing and sale of breakthrough cannabis-based
medicines, announces that LVL Health, its private pain clinic
subsidiary, has concluded the feasibility study of its non-cancer
chronic pain clinical trial and the results have been formally
submitted to the Research Ethics Committee ("REC") in line with the
timings provided in the Interim results announced on 29 September
2022.
The feasibility study was designed to demonstrate LVL's ability
to engage and retain patients and was requested by REC prior to REC
approval of the larger clinical trial which would allow for the
enrolment of up to 5,000 patients. The design of the larger
clinical trial has already been conditionally approved by the MHRA
and enrolment will commence upon receipt of approval from REC.
James Short, CEO of Celadon, commented:
"The Company is pleased to confirm that its feasibility study
has concluded and we have submitted the positive results to REC.
Everything we do at Celadon starts with the patient, and the
results from the study we have seen in terms of improvements in
quality of life in recent months have been tremendous. Our
longstanding aim remains, and we continue to strive, to open up the
UK market by giving doctors confidence in prescribing."
"The planned, larger clinical trial has the potential to provide
the most robust data set to-date in the UK for cannabis-based
medicines. It was designed in collaboration with the MHRA to
provide a data set that will enable the potential for prescription
and reimbursement by the National Health Service."
Enquiries:
Celadon Pharmaceuticals Plc
James Short Via Powerscourt
Arthur Wakeley
Canaccord Genuity Limited (Nominated
Adviser and Broker)
Bobbie Hilliam / Andrew Potts / Patrick
Dolaghan +44 (0)20 7523 8000
Powerscourt Group
Sarah MacLeod / Nick Johnson / Sam Austrums
/
Ibrahim Khalil +44 (0)20 7250 1446
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company
focused on the research, cultivation, manufacturing, and sale of
breakthrough cannabis-based medicines. Its primary focus is on
improving quality of life for chronic pain sufferers, as well as
exploring the potential of cannabis-based medicines for other
conditions such as autism. Its 100,000 sq. ft UK facility comprises
a laboratory designed to meet GMP standards, and capacity for a
large indoor hydroponic growing facility that has received a Home
Office Licence to legally grow high-THC medicinal cannabis for the
purpose of producing test batches of cannabis oil to support its
application to the MHRA. The Company's subsidiary, LVL, owns a MHRA
conditionally-approved cannabis trial using cannabis based
medicinal products to treat chronic pain in the UK. Celadon also
has a minority interest in early-stage biopharma Kingdom
Therapeutics which is developing a licenced cannabinoid medicine to
treat children with Autism Spectrum Disorder.
For further information please visit our website
www.celadonpharma.co.uk
This announcement contains inside information for the purposes
of article 7 of the Market Abuse Regulation (EU) 596/2014 as
amended by regulation 11 of the Market Abuse (Amendment) (EU Exit)
Regulations 2019/310. With the publication of this announcement,
this information is now considered to be in the public domain.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGZMZZLLVGZZM
(END) Dow Jones Newswires
December 30, 2022 02:00 ET (07:00 GMT)
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Apr 2024 to May 2024
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From May 2023 to May 2024